Vinicius Andreoli Schoeps
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vinicius Andreoli Schoeps has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Akash Virupakshaiah
Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco
12 shared publications - Emmanuelle Waubant
Department of Neurology University of California San Francisco San Francisco California USA
10 shared publications Emmanuelle Waubant
9 shared publications- Lauren B. Krupp
Pediatric MS Center, NYU Langone Health, New York, New York, USA
6 shared publications - Tanuja Chitnis
Department of Neurology, Mass General Brigham, Boston, MA, USA
6 shared publications - Aaron W. Abrams
Cleveland Clinic, OH
5 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Elsevier in Cell Reports Medicine
Propionate, a short-chain fatty acid, is associated with disease activity in pediatric-onset multiple sclerosis
- 6 November 2026
- Published by Elsevier in Cell Reports Medicine
Open AccessPropionate, a short-chain fatty acid, is associated with disease activity in pediatric-onset multiple sclerosis
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218508
Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Background and ObjectivesThe most effective treatment strategy to prevent relapses after a first myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) event remains unclear. Our o...
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218508
Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Background and ObjectivesThe most effective treatment strategy to prevent relapses after a first myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) event remains unclear. Our o...
- Open Access
- 11 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial
To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0–6.5) to receive high-dose oral N -acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594). Using the Olink proximity extension assay, we measured 20 serum biomarkers at baseline and 4 weeks on treatment. NAC resulted in decreased glial fibrillary acidic protein (median change: −10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression.
- 11 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
Open AccessHigh-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial
To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0–6.5) to receive high-dose oral N -acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594). Using the Olink proximity extension assay, we measured 20 serum biomarkers at baseline and 4 weeks on treatment. NAC resulted in decreased glial fibrillary acidic protein (median change: −10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression.
- 10 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 818-828
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study
Background: Multiple sclerosis (MS) is increasingly recognized as having a prodromal phase, characterized by non-specific symptoms preceding demyelinating events, yet prospective, longitudinal assessments of relevant signs before the first MS symptom are lacking. Objectives: To investigate whether a wide range of signs and symptoms occurred more frequently in individuals who later developed MS than in the underlying cohort. Methods: We followed 113,876 women from the Nurses’ Health Study II with prospectively collected data on lifestyle, health indicators, and diet. We examined the trajectory of these factors relative to the date of first symptom in 336 incident MS cases compared with the underlying cohort. Results: Several medical conditions, including migraine, depression, urinary leakage, and restless legs syndrome, were more prevalent in individuals who subsequently developed clinical MS. For example, the prevalence of migraine surpassed the underlying cohort 9–10 years before onset and reached 22.8% versus 19.3% at the time of first symptom. Furthermore, a decline in physical activity, physical function, and vitality occurred years before the first MS symptoms. Dietary changes were less pronounced. Conclusion: Several health indicators deteriorated years before typical MS symptoms emerged, suggesting that MS is preceded by a prodromal phase characterized by both specific and non-specific symptoms.
- 10 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 818-828
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study
Background: Multiple sclerosis (MS) is increasingly recognized as having a prodromal phase, characterized by non-specific symptoms preceding demyelinating events, yet prospective, longitudinal assessments of relevant signs before the first MS symptom are lacking. Objectives: To investigate whether a wide range of signs and symptoms occurred more frequently in individuals who later developed MS than in the underlying cohort. Methods: We followed 113,876 women from the Nurses’ Health Study II with prospectively collected data on lifestyle, health indicators, and diet. We examined the trajectory of these factors relative to the date of first symptom in 336 incident MS cases compared with the underlying cohort. Results: Several medical conditions, including migraine, depression, urinary leakage, and restless legs syndrome, were more prevalent in individuals who subsequently developed clinical MS. For example, the prevalence of migraine surpassed the underlying cohort 9–10 years before onset and reached 22.8% versus 19.3% at the time of first symptom. Furthermore, a decline in physical activity, physical function, and vitality occurred years before the first MS symptoms. Dietary changes were less pronounced. Conclusion: Several health indicators deteriorated years before typical MS symptoms emerged, suggesting that MS is preceded by a prodromal phase characterized by both specific and non-specific symptoms.
- 29 May 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (10) , 1014-1021
Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis
Background: Epstein–Barr virus (EBV) is a key environmental risk factor for multiple sclerosis (MS), and tonsils and adenoids serve as a primary viral reservoir. This study investigates the potential role of adenotonsillectomy in pediatric-onset multiple sclerosis (POMS) risk and relapse rate. Objectives: POMS participants and controls were recruited from 16 pediatric MS clinics between 1 November 2011 and 1 July 2017. Clinical and demographic information, including history of adenotonsillectomy, EBV serostatus, and HLA-DRB1*15:01:01 status, were collected. Multivariable logistic regression assessed the association between adenotonsillectomy and MS risk. In addition, negative binomial regression offset by follow-up time was used to assess the relationship between adenotonsillectomy and relapse rate in POMS participants with available follow-up data. Results: The case-control analysis included 359 POMS participants and 560 pediatric controls. Individuals with a history of adenotonsillectomy had a 63% increased odds of MS (adjusted odds ratio (OR) = 1.63, 95% confidence interval (CI) = 1.01–2.64, p = 0.046). Among the 239 POMS participants with available follow-up data, adenotonsillectomy was associated with a twofold increase in annualized relapse rate (adjusted incidence rate ratio (IRR) = 2.00, 95% CI = 1.15–3.48, p = 0.013). Conclusions: Prior adenotonsillectomy was associated with increased risk of MS and greater relapse rate in pediatric patients, suggesting a potential interplay between EBV, immune regulation, and MS pathogenesis.
- 29 May 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (10) , 1014-1021
Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis
Background: Epstein–Barr virus (EBV) is a key environmental risk factor for multiple sclerosis (MS), and tonsils and adenoids serve as a primary viral reservoir. This study investigates the potential role of adenotonsillectomy in pediatric-onset multiple sclerosis (POMS) risk and relapse rate. Objectives: POMS participants and controls were recruited from 16 pediatric MS clinics between 1 November 2011 and 1 July 2017. Clinical and demographic information, including history of adenotonsillectomy, EBV serostatus, and HLA-DRB1*15:01:01 status, were collected. Multivariable logistic regression assessed the association between adenotonsillectomy and MS risk. In addition, negative binomial regression offset by follow-up time was used to assess the relationship between adenotonsillectomy and relapse rate in POMS participants with available follow-up data. Results: The case-control analysis included 359 POMS participants and 560 pediatric controls. Individuals with a history of adenotonsillectomy had a 63% increased odds of MS (adjusted odds ratio (OR) = 1.63, 95% confidence interval (CI) = 1.01–2.64, p = 0.046). Among the 239 POMS participants with available follow-up data, adenotonsillectomy was associated with a twofold increase in annualized relapse rate (adjusted incidence rate ratio (IRR) = 2.00, 95% CI = 1.15–3.48, p = 0.013). Conclusions: Prior adenotonsillectomy was associated with increased risk of MS and greater relapse rate in pediatric patients, suggesting a potential interplay between EBV, immune regulation, and MS pathogenesis.
- Open Access
- 14 May 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71386
The Effect of Ocrelizumab on Anti‐JC Virus Antibody Index
Purpose/Introduction: The anti‐JC virus (JCV) antibody index is used to stratify the risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS), particularly with natalizumab therapy. B‐cell‐depleting therapies may alter antibody levels and potentially confound the estimation of PML risk. This study evaluated the effect of ocrelizumab on anti‐JCV antibody indices during the first 2 years of treatment. Methods: We conducted a retrospective cohort study of 553 MS patients who initiated ocrelizumab between 2017 and 2019. Anti‐JCV antibody indices were measured using the STRATIFY JCV assay at baseline and approximately every 6 months prior to subsequent infusions. Linear mixed‐effects models were used to assess longitudinal changes in log‐transformed JCV indices, adjusting for age, sex, and ethnicity. Secondary analyses evaluated serum B‐cell counts and immunoglobulin levels. Sensitivity analyses addressed missing data. Results/Finding: There was no significant change in anti‐JCV antibody index over time following ocrelizumab initiation (mean percent change per infusion cycle −0.049%, 95% CI: −0.449 to 0.351; p = 0.81). Results were consistent across sensitivity analyses and did not differ by age or sex. In contrast, peripheral B‐cell counts declined significantly after treatment initiation and remained suppressed. Serum IgG, IgM, and IgA levels decreased modestly but significantly over time. JCV seroconversion occurred in 4.1% of initially seronegative patients, while seroreversion occurred in 6.6% of initially seropositive patients. Conclusion: Anti‐JCV antibody indices remain stable during the first 2 years of ocrelizumab treatment despite marked B‐cell depletion and modest reductions in serum immunoglobulins. These findings suggest that existing PML risk stratification tools based on anti‐JCV antibody indices remain applicable during early ocrelizumab therapy.
- 14 May 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (5) , e71386
Open AccessThe Effect of Ocrelizumab on Anti‐JC Virus Antibody Index
Purpose/Introduction: The anti‐JC virus (JCV) antibody index is used to stratify the risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS), particularly with natalizumab therapy. B‐cell‐depleting therapies may alter antibody levels and potentially confound the estimation of PML risk. This study evaluated the effect of ocrelizumab on anti‐JCV antibody indices during the first 2 years of treatment. Methods: We conducted a retrospective cohort study of 553 MS patients who initiated ocrelizumab between 2017 and 2019. Anti‐JCV antibody indices were measured using the STRATIFY JCV assay at baseline and approximately every 6 months prior to subsequent infusions. Linear mixed‐effects models were used to assess longitudinal changes in log‐transformed JCV indices, adjusting for age, sex, and ethnicity. Secondary analyses evaluated serum B‐cell counts and immunoglobulin levels. Sensitivity analyses addressed missing data. Results/Finding: There was no significant change in anti‐JCV antibody index over time following ocrelizumab initiation (mean percent change per infusion cycle −0.049%, 95% CI: −0.449 to 0.351; p = 0.81). Results were consistent across sensitivity analyses and did not differ by age or sex. In contrast, peripheral B‐cell counts declined significantly after treatment initiation and remained suppressed. Serum IgG, IgM, and IgA levels decreased modestly but significantly over time. JCV seroconversion occurred in 4.1% of initially seronegative patients, while seroreversion occurred in 6.6% of initially seropositive patients. Conclusion: Anti‐JCV antibody indices remain stable during the first 2 years of ocrelizumab treatment despite marked B‐cell depletion and modest reductions in serum immunoglobulins. These findings suggest that existing PML risk stratification tools based on anti‐JCV antibody indices remain applicable during early ocrelizumab therapy.
- Open Access
- 29 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (2)
Epidemiology of neuromyelitis optica spectrum disease in Central-West Brazil: Prevalence and associated clinical and demographic features
Background: Neuromyelitis optica spectrum diseases (NMOSD) are rare autoimmune diseases of the central nervous system. Although Brazil reports one of the highest global prevalences of NMOSD, regional data, particularly from the Central-West, remain limited. Objectives: To characterize the epidemiological, laboratory, and therapeutic profiles of NMOSD patients residing in Brazil's Federal District, based on 2015 international diagnostic criteria. Methods: This prospective observational study analyzed data from 55 consecutive NMOSD patients entered as new records in the Brazilian Registry of Neurological Diseases (REDONE.br) between July 2023 and July 2025. Statistical analyses included descriptive methods, between-group comparisons, and multivariable logistic-regression. Results: The cohort comprised 45 women (81.8%), with a mean age of onset of 36.85 ± 14.89 years. Myelitis was the most frequent initial presentation (76.4%), followed by unilateral optic neuritis (45.5%). The socioeconomic profile revealed marked vulnerability: 65.5% reported family income ≤2 minimum wages, and 45.5% were unemployed. Rituximab was the most frequently used disease-modifying therapy. The estimated NMOSD prevalence was 1.84 cases per 100,000 inhabitants (95% CI: 1.38–2.39), and the prevalence of antiAQP4 + was 1.64 cases per 100,000 (95% CI: 1.21–2.16). Conclusions: This study provides a comprehensive characterization of NMOSD in Brazil's Central-West region and highlights that the disease disproportionately affects individuals living in conditions of social vulnerability.
- 29 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (2)
Open AccessEpidemiology of neuromyelitis optica spectrum disease in Central-West Brazil: Prevalence and associated clinical and demographic features
Background: Neuromyelitis optica spectrum diseases (NMOSD) are rare autoimmune diseases of the central nervous system. Although Brazil reports one of the highest global prevalences of NMOSD, regional data, particularly from the Central-West, remain limited. Objectives: To characterize the epidemiological, laboratory, and therapeutic profiles of NMOSD patients residing in Brazil's Federal District, based on 2015 international diagnostic criteria. Methods: This prospective observational study analyzed data from 55 consecutive NMOSD patients entered as new records in the Brazilian Registry of Neurological Diseases (REDONE.br) between July 2023 and July 2025. Statistical analyses included descriptive methods, between-group comparisons, and multivariable logistic-regression. Results: The cohort comprised 45 women (81.8%), with a mean age of onset of 36.85 ± 14.89 years. Myelitis was the most frequent initial presentation (76.4%), followed by unilateral optic neuritis (45.5%). The socioeconomic profile revealed marked vulnerability: 65.5% reported family income ≤2 minimum wages, and 45.5% were unemployed. Rituximab was the most frequently used disease-modifying therapy. The estimated NMOSD prevalence was 1.84 cases per 100,000 inhabitants (95% CI: 1.38–2.39), and the prevalence of antiAQP4 + was 1.64 cases per 100,000 (95% CI: 1.21–2.16). Conclusions: This study provides a comprehensive characterization of NMOSD in Brazil's Central-West region and highlights that the disease disproportionately affects individuals living in conditions of social vulnerability.
- 20 February 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (4) , 421-428
Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis
Objectives: Biological age may better capture differences in disease course among people with multiple sclerosis (PwMS) of identical chronological age. We investigated biological age acceleration through metabolomic age (mAge) in PwMS and its association with social determinants of health (SDoH) measured by area deprivation index (ADI). Methods: mAge was calculated for two cohorts: 323 PwMS and 66 healthy controls (HCs); 101 HCs and 71 DMT-naïve PwMS, using an aging clock derived from 11,977 healthy adults. mAge acceleration, the difference between mAge and chronological age, was compared between groups using generalized linear and mixed-effects models, and its association with ADI was assessed via linear regression. Results: Estimated mAge showed a modest correlation with chronological age (R 2 ≈0.20–0.25). Cross-sectionally, PwMS had higher age acceleration than HCs: 9.77 years in adult PwMS (95% CI: 6.57–12.97, p = 5.3e-09), and 4.90 years in adult DMT-naïve PwMS (95% CI: 0.85–9.01, p = 0.02). Longitudinally, PwMS aged 1.19 mAge years per chronological year (95% CI: 0.18–2.20; p = 0.02), faster than HCs. In PwMS, a 10-percentile increase in ADI was associated with a 0.63-year (95% CI: 0.10–1.18; p = 0.02) increase in age acceleration. Discussion: We demonstrated accelerated mAge in PwMS and its association with social disadvantage.
- 20 February 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (4) , 421-428
Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis
Objectives: Biological age may better capture differences in disease course among people with multiple sclerosis (PwMS) of identical chronological age. We investigated biological age acceleration through metabolomic age (mAge) in PwMS and its association with social determinants of health (SDoH) measured by area deprivation index (ADI). Methods: mAge was calculated for two cohorts: 323 PwMS and 66 healthy controls (HCs); 101 HCs and 71 DMT-naïve PwMS, using an aging clock derived from 11,977 healthy adults. mAge acceleration, the difference between mAge and chronological age, was compared between groups using generalized linear and mixed-effects models, and its association with ADI was assessed via linear regression. Results: Estimated mAge showed a modest correlation with chronological age (R 2 ≈0.20–0.25). Cross-sectionally, PwMS had higher age acceleration than HCs: 9.77 years in adult PwMS (95% CI: 6.57–12.97, p = 5.3e-09), and 4.90 years in adult DMT-naïve PwMS (95% CI: 0.85–9.01, p = 0.02). Longitudinally, PwMS aged 1.19 mAge years per chronological year (95% CI: 0.18–2.20; p = 0.02), faster than HCs. In PwMS, a 10-percentile increase in ADI was associated with a 0.63-year (95% CI: 0.10–1.18; p = 0.02) increase in age acceleration. Discussion: We demonstrated accelerated mAge in PwMS and its association with social disadvantage.
- Open Access
- 24 June 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 837-850
High‐Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis
Objective: Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to resolution of inflammation (pseudoatrophy) and confounding the interpretation of atrophy. High‐dose glucocorticoids (HDGs) reduce inflammation and might therefore modify pseudoatrophy. Methods: One hundred twenty‐three newly diagnosed and DMT‐naïve MS participants (relapsing–remitting, 70% female participants, median age = 36 years, Expanded Disability Status Scale [EDSS] 2.0) were followed for up to 3 years. Forty‐two participants received HDG before baseline magnetic resonance imaging (MRI; DMT‐HDG; median = 52 days, interquartile range [IQR] = 37–71), whereas 60 did not (DMT/no‐HDG). Twenty‐one participants remained untreated (no‐DMT), and 102 started DMT after baseline MRI. SC total cervical cord cross‐sectional area (TCA), gray matter area (GMA), and white matter area (WMA) and regional brain volumes were analyzed using mixed effects models. Results: The DMT‐HDG, DMT/no‐HDG, and no‐DMT groups had similar demographic, clinical, and radiological features. Pronounced SC pseudoatrophy was observed based on more year 1 versus year 2 volume loss for DMT/no‐HDG (−2.06% vs. 0.83%; P = 0.02) but not DMT‐HDG (−0.51% vs. 0.66%; P = 0.8) and more year 1 volume loss for DMT/no‐HDG compared to DMT‐HDG (−2.06% vs. 0.51%; P = 0.02). Interpretation: HDG preceding baseline MRI suppresses CNS white matter (WM) pseudoatrophy after DMT initiation, most conspicuously for the SC. Suppression of pseudoatrophy with HDG may improve the fidelity of clinical trials and enhance the feasibility for short‐term trials with SC and brain MRI outcomes in active MS by pretreatment with HDG. ANN NEUROL 2025;98:837–850
- 24 June 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 837-850
Open AccessHigh‐Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis
Objective: Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to resolution of inflammation (pseudoatrophy) and confounding the interpretation of atrophy. High‐dose glucocorticoids (HDGs) reduce inflammation and might therefore modify pseudoatrophy. Methods: One hundred twenty‐three newly diagnosed and DMT‐naïve MS participants (relapsing–remitting, 70% female participants, median age = 36 years, Expanded Disability Status Scale [EDSS] 2.0) were followed for up to 3 years. Forty‐two participants received HDG before baseline magnetic resonance imaging (MRI; DMT‐HDG; median = 52 days, interquartile range [IQR] = 37–71), whereas 60 did not (DMT/no‐HDG). Twenty‐one participants remained untreated (no‐DMT), and 102 started DMT after baseline MRI. SC total cervical cord cross‐sectional area (TCA), gray matter area (GMA), and white matter area (WMA) and regional brain volumes were analyzed using mixed effects models. Results: The DMT‐HDG, DMT/no‐HDG, and no‐DMT groups had similar demographic, clinical, and radiological features. Pronounced SC pseudoatrophy was observed based on more year 1 versus year 2 volume loss for DMT/no‐HDG (−2.06% vs. 0.83%; P = 0.02) but not DMT‐HDG (−0.51% vs. 0.66%; P = 0.8) and more year 1 volume loss for DMT/no‐HDG compared to DMT‐HDG (−2.06% vs. 0.51%; P = 0.02). Interpretation: HDG preceding baseline MRI suppresses CNS white matter (WM) pseudoatrophy after DMT initiation, most conspicuously for the SC. Suppression of pseudoatrophy with HDG may improve the fidelity of clinical trials and enhance the feasibility for short‐term trials with SC and brain MRI outcomes in active MS by pretreatment with HDG. ANN NEUROL 2025;98:837–850
- Open Access
- 1 March 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (2) , e200375
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis
Low sun and ultraviolet radiation (UVR) exposures have been associated with increased risk of developing pediatric-onset multiple sclerosis (MS); however, their effect on disease course has not been well characterized. We primarily investigated whether there was an association between time spent in the sun in early childhood and risk of relapse in pediatric MS. We secondarily investigated the effect of sun exposure during more recent periods on risk of relapse. We conducted a multicenter cohort study of participants with pediatric-onset MS recruited from 18 pediatric MS clinics across the United States between November 1, 2011, and July 1, 2017. Relapses were identified prospectively after study enrollment; relapses preceding study enrollment were entered retrospectively. Time spent in the sun at various periods of life was measured using a detailed environmental questionnaire, and ambient UVR exposure was determined using zip codes. Multivariable Cox regression models were used to assess the association between time spent in the sun and UVR dose at specific periods of life and the risk of relapse. Models were adjusted for demographic, clinical, and sun exposure-related characteristics. In our cohort of 334 children with MS, 206 (62%) experienced at least one relapse from disease onset to the end of the follow-up period. After adjustment, ≥30 minutes of daily sun exposure during the first summer of life was associated with a lower risk of relapse compared with p = 0.01). Greater time spent in the sun during the second trimester of pregnancy was also associated with reduced risk of relapse (aHR 0.68, CI 0.48-0.97, p = 0.04). UVR dose and time spent in the sun later in life were not significantly associated with relapse risk. In this large cohort study of children with MS, greater early childhood and prenatal sun exposure time was associated with lower risk of relapse. Further investigation of sun exposure at other periods is needed to better characterize its impact on disease course and guide potential future interventions.
- 1 March 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (2) , e200375
Open AccessAssociation Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis
Low sun and ultraviolet radiation (UVR) exposures have been associated with increased risk of developing pediatric-onset multiple sclerosis (MS); however, their effect on disease course has not been well characterized. We primarily investigated whether there was an association between time spent in the sun in early childhood and risk of relapse in pediatric MS. We secondarily investigated the effect of sun exposure during more recent periods on risk of relapse. We conducted a multicenter cohort study of participants with pediatric-onset MS recruited from 18 pediatric MS clinics across the United States between November 1, 2011, and July 1, 2017. Relapses were identified prospectively after study enrollment; relapses preceding study enrollment were entered retrospectively. Time spent in the sun at various periods of life was measured using a detailed environmental questionnaire, and ambient UVR exposure was determined using zip codes. Multivariable Cox regression models were used to assess the association between time spent in the sun and UVR dose at specific periods of life and the risk of relapse. Models were adjusted for demographic, clinical, and sun exposure-related characteristics. In our cohort of 334 children with MS, 206 (62%) experienced at least one relapse from disease onset to the end of the follow-up period. After adjustment, ≥30 minutes of daily sun exposure during the first summer of life was associated with a lower risk of relapse compared with p = 0.01). Greater time spent in the sun during the second trimester of pregnancy was also associated with reduced risk of relapse (aHR 0.68, CI 0.48-0.97, p = 0.04). UVR dose and time spent in the sun later in life were not significantly associated with relapse risk. In this large cohort study of children with MS, greater early childhood and prenatal sun exposure time was associated with lower risk of relapse. Further investigation of sun exposure at other periods is needed to better characterize its impact on disease course and guide potential future interventions.